Background Difficulties persist in differentiating pancreatic ductal adenocarcinomas (PDAC) from pancreatic inflammatory masses (PIM). Auxiliary diagnostic techniques which enhance the endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) diagnostic yield have been attempted, for example, K-ras mutation analysis. We aimed to evaluate the accuracy of K-ras mutation analysis combined with EUS-FNA for the differential diagnosis of PDAC and PIM by pooling data of existing trials. Methods We systematically searched the Medline, PubMed, Web of Science, Embase, and Cochrane Central Trials databases for relevant published studies. Meta-analysis was performed. Pooling was conducted in fixed-effect model or random-effect model.
P ancreatic ductal adenocarcinomas (PDAC) carry a dismal prognosis, with fewer than 5% of patients surviving five years. 1 Difficulties persist relating to early diagnosis of PDAC and in differentiating PDAC from pancreatic inflammatory masses (PIM), which leads to unnecessary resection of benign lesions and delayed treatment of PDAC. Thus, early and expeditious diagnosis of pancreatic malignancy is crucial.
In recent years, endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) has become the best method for establishing a differential diagnosis for pancreatic masses. [2] [3] [4] However, the small amount of acquired specimens and/ or inconclusive cytological analysis imposes limits on its diagnostic efficacy, with sensitivity quite variable ranging from 65% to 95% and negative predictive values ranging from 50% to 70%. 2, [4] [5] [6] Moreover, EUS-FNA may be inconclusive in up to 20% patients considering atypical cell diagnosis, thus creates a management dilemma as this diagnosis is considered insufficient for initiation of chemotherapy or surgery.. [2] [3] [4] 7 In this setting, many auxiliary diagnostic techniques have been attempted to enhance the diagnostic yield of EUS-FNA, for example, tumor marker analysis.
Among the various genetic markers in PDAC, K-ras is the most frequently studied, with an estimated prevalence of 90%-95%. 8 A series of studies have evaluated the utility of K-ras mutation analysis in EUS-FNA samples to detect PDAC and showed that, when combined with cyto-/histological findings obtained via EUS-FNA, K-ras mutation analysis appeared to be highly accurate, with sensitivity ranging from 81% to 97% and specificity ranging from 55% to 100%. [9] [10] [11] [12] [13] [14] [15] [16] The main objective of this study was to perform a meta-analysis of published information to assess whether combining EUS-FNA with K-ras mutation analysis might be effective in the differential diagnosis between PDAC and a pseudotumoral form of inflammatory mass, and to further clarify the incremental benefit of K-ras mutation analysis over the conventional EUS-FNA.
METHODS

Research methods
We performed a comprehensive literature search by using the Medline, PubMed, Web of Science, Embase, and Cochrane Central Trials databases. The search terms were "EUS or endoscopic ultrasonography or endoscopic ultrasound or ultrasonography or endosonography" and "fine-needle or FNA" and "K-ras or KRAS or ki-ras" and "pancreas". All references of the retrieved articles were scrutinized to identify any additional articles that might have been missed by the former search. Two investigators independently searched and extracted the data. Disagreements were resolved by discussion. If any clarification of data was necessary, the authors were contacted for detailed information.
Study selection
Inclusion criterias were as follows: (1) the technique of K-ras mutation analysis using EUS-FNA samples was performed in pancreatic diseases; (2) diagnostic clinical trials evaluating the accuracy of EUS-FNA and K-ras mutation analysis for the differential diagnosis of PDAC and PIM; (3) using unequivocal histo-/cytopathologic evaluation of EUS-FNA samples, histopathology of surgical specimens, or a follow-up period of at least 6 months as reference standard; and (4) providing sufficient data to construct a 2×2 table for true positive, false positive, false negative, and true negative.
Studies were excluded if they met the following criteria: (1) no evaluation of solid lesions of the pancreas; (2) incomplete data available; (3) overlapping with the selected studies (i.e., studies from the same study group, institution, and period of inclusion); (4) reviews, editorials, and corresponding letters that did not report their own data; and (5) case reports and meeting abstracts.
Statistical methods
Meta-analysis for the accuracy of K-ras mutation analysis combined with EUS-FNA cytological examination was performed by calculating pooled estimates of sensitivity, specificity, positive likelihood ratio (LR), and negative LR. Pooling results (with corresponding 95% CI) were derived by using the fixed-effect model (Mantel-Haenszel method) 17 when significant heterogeneity was not present.
The random-effect model (DerSimonian-Laird method) 18 was applied otherwise. The Cochrane Q test was estimated to detect the heterogeneity among studies. P-values of less than 0.1 indicated the presence of heterogeneity. 19 Inconsistency (I 2 ) was calculated to describe the percentage of the variability attributable to heterogeneity rather than sampling errors. I 2 >25% was considered significant for heterogeneity. A summary receiver-operating characteristic (SROC) curve was constructed using the Moses-Shapiro-Littenberg method as a way to summarize the truepositive and false-positive rates from different studies. 20 The area under the curve (AUC) was calculated, with the value ranging from 0.5 to 1.0. An AUC close to 0.5 indicated a poor test, and an AUC of 1.0 indicated a perfect test. 21 Furthermore, to explore the potential sources of heterogeneity, we used meta-regression to estimate the effect of the following characteristics of the studies on the diagnostic accuracy of the combination of EUS-FNA and K-ras mutation analysis: 22 number of patients (number ≥50 vs. number <50), methods for detecting K-ras gene mutation (restriction fragment length polymorphism (PCR-RFLP) vs. others), detected mutation points of K-ras (codon 12 alone vs. others), and country (Japan vs. others). A P-value of less than 0.05 indicated significance. In addition, the outliers were identified by inspecting the plots of sensitivity, specificity, positive LR, negative LR, and SROC curve. A subgroup analysis was performed by excluding the outliers. 23, 24 The characteristics of the outliers were further investigated to explain the cause of heterogeneity. Assessment of publication bias was performed by the Begg-Mazumdar indictor. 25 P-values of less than 0.1 indicated the presence of publication bias. Besides, we constructed funnel plots to analyze the publication bias in the selected studies. The Quality Assessment of Diagnostic Accuracy Studies (QUADAS) questionnaire was used to assess the quality of the selected studies. 26 Items were rated as yes, no, or unclear. Pooled weighted sensitivity, specificity, positive LR, negative LR, SROC curve, and meta-regression were performed using Meta-Disc version 1.4 (Unit of Clinical Biostatistics, Ramony Cajal Hospital, Madrid, Spain). 27 Publication bias analysis was conducted using Stata version 10.0 (Stata Corporation, College Station, TX, USA).
RESULTS
Eligible studies and quality assessment
A flow chart describing the procedure of study selection is shown in Figure 1 . The initial literature search using the predefined search strategy yielded 281 full-text articles. Finally, eight studies fulfilled the inclusion criteria and were included in this meta-analysis. The characteristics of the selected studies are listed in Table 1 . All studies were published as full text. A total of 696 cases of PDAC and 138 cases of PIM were investigated in the analysis. The mean tumor size ranged from 29 to 42 mm. Among total 123 patients whose EUS-FNA results were inconclusive or negative, fifty-nine had K-ras mutations and were finally diagnosed with PDAC (48%, 59/123). Four of the eight studies detected K-ras mutations in codon 12, and the methods for detecting K-ras gene mutations included PCR-RFLP, PCR-SSCP (single-strand conformation polymorphism), and some others. Data for evaluating the accuracy of the combination of K-ras mutation analysis with EUS-FNA for the differential diagnosis of PDAC and PIM was extracted from these studies.
The quality of the eligible studies, as assessed according to the QUADAS criteria, is reported in Figure 2 . The percentage of high-quality studies (i.e., those for which a yes response applied) varied between 50% and 100% for each of the 14 items. For most QUADAS items (10/14), all studies were classified as high quality, whereas for three of them (i.e., index test interpreted blindly, reference standard independent of the index test, same reference regardless of the index test), the proportion of high-quality studies was no more than 50%.
Differential diagnosis of PDAC and PIM
For the differential diagnosis of PDAC and PIM, the combination of K-ras mutation analysis and EUS-FNA demonstrated a high diagnostic value with a pooled sensitivity (random-effect model) of 90% (95% CI 88%-92%) and a pooled specificity (random-effect model) of 95% (95% CI 90%-98%; Figure 3 ). AUC under SROC for K-ras mutation analysis with EUS-FNA was 0.9348 ( Figure   4 ). There was significant heterogeneity in pooled sensitivity and specificity among the studies.
Combined application of K-ras mutation analysis with EUS-FNA had a pooled positive LR (random-effect model) of 13.45 (95% CI 2.69-69.27) and a pooled negative LR (random-effect model) of 0.13 (95% CI 0.18-0.21) in the differential diagnosis of PDAC and PIM ( Figure 5 ). Significant heterogeneity was found in pooled positive LR and negative LR among the studies.
Test for heterogeneity
The meta-regression did not show any relationship between the characteristics of the studies and the diagnostic odds ratio ( Table 2) . A check of Figures 4 and 5 showed that the studies by Reicher et al 14 and Wang et al 16 were the outliers. The subgroup analysis showed that the heterogeneities were eliminated in pooled estimates when the outliers were excluded ( Table 3) .
Bias estimate
The Begg-Mazumdar indicator did not indicate publication bias for combined application of K-ras mutation analysis with EUS-FNA (Kendall's tau b = -14, P = 0.083) for differentiating PDAC from PIM. The funnel plot is shown in Figure 6 .
DISCUSSION
EUS-FNA is widely regarded as a reliable and accurate diagnostic tool for solid pancreatic neoplasms; however, its diagnostic efficacy is always reduced by the fact that in addition to the unequivocally assigned samples, a relatively high percentage of FNA smears are marked as inconclusive due to poor cellularity, absence of epithelial cells, presence of only blood clot, or presence of only normal cells. This mirrors the fact that the distinction between PIM and PDAC may be problematic and cause underdiagnosis of pancreatic cancer. Hence, additional diagnostic tools are urgently needed for FNA cytology.
Various genetic abnormalities, such as K-ras, p53, and p16, have been demonstrated in PDAC, [28] [29] [30] with K-ras being one of the most frequent. We have demonstrated from this metaanalysis of diagnostic accuracy that K-ras mutation analysis combined with EUS-FNA performs well as a diagnostic test for solid pancreatic neoplasms, with a pooled sensitivity of 90% (95% CI 88%-92%) and a pooled specificity of 95% (95% CI 90%-98%). A combination of K-ras mutation analysis and EUS-FNA also has a high positive LR (13.45 (95% CI 2.69-69.27)) and a reasonable negative LR (0.13 (95% CI 0.18-0.21)). Addition of K-ras mutation analysis improves the diagnostic yield of EUS-FNA especially when the cytopathology is inconclusive or perhaps inadequate in the case of a pancreatic mass, since the presence of a K-ras mutation is highly suggestive of adenocarcinoma.
Among the eight included studies, there were 123 cases that did not receive a diagnosis of malignancy by histo-/ cytopathological evaluation of the EUS-FNA samples alone, of whom K-ras gene mutations were found and finally diagnosed as PDAC in 59 cases(48%, 59/123; Table  1 ). This encouraging result indicated that K-ras mutation analysis did add a significantly incremental benefit especially to patients who have a mass in the pancreas with an indeterminate evaluation.
K-ras is mutated in over 90% of PDAC, with the majority of mutations occurring in codon 12, rarely in codons 13 and 61. 31, 32 The common methods for detecting K-ras gene mutation were mainly divided into two groups: PCR-SSCP 11, 14, 15 and PCR-RFLP. 10, 12, 13 When PCR-SSCP was used to evaluate samples that contained both normal and cancerous tissues, false-negative results were common. Using the PCR-RFLP method easily produces falsepositive data. 16 Besides, four studies 9-12 evaluated only codon 12. Although single-point mutation that activates the oncogenic potential of K-ras occurs most commonly on codon 12, additional point mutations of K-ras have also been identified, such as those on codons 13 and 61. There were several other included studies. 13, 14, 16 which evaluated both codons 12 and 13. Among them, Reicher et al 14 also detected codon 61. Considering all these factors, we performed a meta-regression and the result did not show any relationship between the methods, mutation point detection, and the diagnostic odds ratio ( Table 2) .
PIM always presents with localized, inflammatory lesions, pancreatic duct irregularity, or even stenosis. These nonspecific characteristics cause difficulty in the differential diagnosis between PIM and PDAC and even the use of EUS-FNA is not always informative. Molecular analysis, like K-ras mutation analysis, revealed its superiority for the diagnosis in this study; five studies [9] [10] [11] 13, 15 included in this meta-analysis reported as high as 100% specificity using K-ras analysis alone which meant the absence or presence of a low amount of K-ras gene mutation from aspirated materials by EUS-FNA suggesting benign pancreatic disorder. However, the presence of K-ras mutations was not entirely specific and false-positive cases were reported by several other studies too. 12, 14, 16 As is widely recognized, mutant K-ras can cause progression of normal pancreatic duct to PanIN and is an early finding that may represent the potential of progression to malignancy. So the presence of K-ras mutation may be of great importance among patients with pancreatic mass and clinical suspicion of PDAC and may not be adequate for population screening.
This meta-analysis summarizes the available evidence of the diagnostic performance of EUS-FNA combined with K-ras analysis for the differential diagnosis of PDAC and PIM. No significant publication bias was found by the Begg-Mazumdar indictor. The inspection of the plots (Figures 3−5) suggested that the studies by Reicher et al 14 and Wang et al 16 were the outliers. First, Reicher et al, who reported a lower sensitivity, used paraffin-embedded tissues for DNA extraction and further K-ras analysis, rather than fresh samples used in most other studies. As is well known, DNA-protein cross-linking caused by formalin fixation may be broken up during the extraction process and also the low pH in unbuffered fixatives leads to degradation of most DNA molecules into fragments of 200 bp or less, 33 both of which result in poor quality of DNA and may be the reason for its lower sensitivity detected in this study. Wang et al reported a lower specificity compared with other studies. They used the novel PNA-PCR clamping method for the detection of K-ras mutations, which were found in 32% (9/28) of non-malignant pancreatic masses, and this seemed to decrease the specificity. Although considered to be false positives with regard to clinical diagnosis for PDAC, these cases still warrant further follow-up for the risk of pancreatic cancer development since K-ras gene mutations were also reported to occur in a subset of precancerous conditions. [34] [35] [36] The subgroup analysis by excluding the outliers eliminated the heterogeneity. The reappraised pooled results still suggested a high diagnostic yield of K-ras analysis combined with EUS-FNA for differential diagnosis of pancreatic adenocarcinomas.
There were two limitations in this study. First, only eight studies were included in the meta-analysis. This small number of studies might reduce the power of the tests on publication bias and source of heterogeneity. 37 Second, different detection methods for K-ras point mutation were used in the selected studies.
In conclusion, our results indicate that combining K-ras mutation analysis with routine cytology moderately improves EUS-FNA in its differential diagnosis between PIM and PDAC, especially for patients with suspected PDAC yet inconclusive EUS-FNA findings and may prove to be a valuable supplemental method to EUS-FNA.
